PANACEABIO · Panacea Biotec Limited · Financials
Volume · Nov 13
2407
Avg daily vol (3M)
5195
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
6.4B
+14.4%
FY2026
Net Income
-53.7M
+35.8%
FY2026
Operating Cash Flow
166.8M
+160.9%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| INR | 6.73B | 6.4B | 5.59B | 5.59B | 4.6B | 6.61B | 6.25B | 5.44B |
| INR | 325.7M | 330.6M | 348.1M | 367.1M | 391.2M | 436.6M | 456M | 432.2M |
| INR | 63.7M | 60.5M | 38.8M | 35.8M | 44.4M | 1.81B | 1.85B | 1.74B |
| INR | -103.6M | -73.7M | -79.5M | 14.8M | 128M | 14.49B | — | — |
| INR | -14.4M | -2.1M | 7.7M | 29.8M | 465.5M | 3.71B | 19.6M | 166.4M |
| INR | -71.2M | -53.7M | -83.7M | -11.7M | 0 | 10.78B | -1.48B | -1.94B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 0 in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.